KALA BIO (KALA) Stock Explodes on Oxford Deal and $10M Offering: What December 4, 2025 Means for Investors
As of December 4, 2025, KALA BIO, Inc. has turned into one of the wildest tickers on the Nasdaq. The stock is trading around $1.40 in heavy volume, up roughly 50% on the day after a cascade of news: a $10 million registered direct offering, a loan settlement that turns lender Oxford Finance into a 16.5% shareholder, and a $6 million rescue-style preferred investment from new CEO David Lazar. All this arrives barely two months after KALA’s lead drug failed a key trial, its lender swept most of its cash, and management warned of “substantial doubt” about its ability to survive as a going concern. GlobeNewswire+3Stock Titan+3Stock Titan+3
